 CytoDyn Inc said that the US Food and Drug Administration FDA has accepted its revised rolling review timeline for the upcoming resubmission of its biologics license application BLA for leronlimab as a combination therapy for highly treatment-experienced HIV patients. A rolling review enables a drug company to submit completed sections of its BLA for review by the FDA, rather than waiting until every section of the BLA is complete before the entire application is reviewed. 